Genpact (NYSE: G) insider transactions
In the twelve months to 10 November 2026, executives and directors of Genpact reported 16 open-market sales of 193,801 shares ($8.1m) and 0 open-market purchases, by 7 people, according to the Form 4 filings they submitted to the SEC.
Latest transactions
| Date | Insider | Role | Transaction | Shares | Price | Held after | Filing |
|---|---|---|---|---|---|---|---|
| 14 September 2026 | Kalra Balkrishan | President and CEO | Open-market sale | −10,000 | $36.79 | 501,114 | Form 4 |
| 9 September 2026 | Pandit Sumita | Chief Financial Officer | Grant or award | +76,713 | — | 76,713 | Form 4 |
| 19 August 2026 | Nanduru Anil | Senior Vice President | Open-market sale | −6,191 | $37.03 | 70,253 | Form 4 |
| 14 August 2026 | Dewan Sameer | Senior Vice President | Open-market sale | −1,654 | $34.10 | 56,011 | Form 4 |
| 14 August 2026 | Dewan Sameer | Senior Vice President | Open-market sale | −13,318 | $34.10 | 42,693 | Form 4 |
| 13 August 2026 | Weiner Michael Hal | Chief Financial Officer | Open-market sale | −5,900 | $34.04 | 176,027 | Form 4 |
| 12 August 2026 | Nanduru Anil | Senior Vice President | Open-market sale | −11,852 | $33.92 | 76,444 | Form 4 |
| 11 August 2026 | Nanduru Anil | Senior Vice President | Open-market sale | −17,243 | $33.96 | 88,296 | Form 4 |
| 23 April 2026 | Morken CeCelia | Director | Grant or award | +6,521 | — | 64,281 | Form 4 |
| 23 April 2026 | Madden James C. | Director | Grant or award | +9,999 | — | 73,067 | Form 4 |
| 23 April 2026 | Gangestad Nicholas C | Director | Grant or award | +6,521 | — | 15,334 | Form 4 |
| 23 April 2026 | Conigliaro Laura | Director | Grant or award | +6,521 | — | 79,337 | Form 4 |
| 23 April 2026 | Hinshaw John M | Director | Grant or award | +6,521 | — | 8,855 | Form 4 |
| 23 April 2026 | Verdi Mark A | Director | Grant or award | +6,521 | — | 71,526 | Form 4 |
| 23 April 2026 | Lindstrom Carol | Director | Grant or award | +6,521 | — | 27,706 | Form 4 |
| 23 April 2026 | Stevens Brian Mark | Director | Grant or award | +6,521 | — | 36,619 | Form 4 |
| 23 April 2026 | Subaiya Thimaya K. | Director | Grant or award | +6,521 | — | 8,541 | Form 4 |
| 10 March 2026 | Mehta Piyush | Senior Vice President and CHRO | Shares withheld for tax | −5,702 | $38.92 | 156,485 | Form 4 |
| 10 March 2026 | Weiner Michael Hal | Chief Financial Officer | Shares withheld for tax | −7,019 | $38.92 | 181,874 | Form 4 |
| 10 March 2026 | Kalra Balkrishan | President and CEO | Shares withheld for tax | −13,893 | $38.92 | 511,114 | Form 4 |
Names appear as in the filing, surname first. A dash in the price column means the filing reports none, as in grants and gifts.
How to read the table
Only open-market purchases and sales are trades the insider chose to make at the market price, and they are the ones counted in the summary above. Grants, option exercises and shares withheld for tax come from pay plans. A sale marked as a 10b5-1 plan was scheduled in advance under a written plan.
Where each row comes from
From the Form 4 that each executive, director or large shareholder must file with the SEC within two business days of a transaction, read up to 10 November 2026. Each row links to its filing on EDGAR. Only transactions in shares are listed, not derivatives, and amended filings are left out. The accounts of the company are on the Genpact page; the method, in data sources.
Information prepared from the Form 4 filings submitted to the SEC, for information purposes only. It is not financial advice or a recommendation to buy or sell. Updated on 12 November 2026.